Trevi Therapeutics, Inc. (TRVI) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$20.48M*; Operating income -$20.51M; Depreciation and amortization $34.00K*.
- 2026-03-31: Basis Reported; EBITDA -$14.88M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$10.19M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$13.88M*; Operating income -$13.92M; Depreciation and amortization $38.00K*.
Complete source-backed ebitda history.
- Available history
- 2022-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$20.48M* | -$20.51M | $34.00K* | (m) | (m) | $124.00K* | -$17.43M* | (m) | $15.15M | (m) | -$19.00K |
|---|
| 2026-03-31 | Reported | -$14.88M | (m) | (m) | (m) | (m) | $102.00K | -$16.69M | (m) | $9.94M | (m) | -$20.00K |
|---|
| 2025-12-31 | Reported | -$10.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$13.88M* | -$13.92M | $38.00K* | (m) | (m) | $12.00K* | -$10.88M* | (m) | $10.09M | (m) | -$15.00K |
|---|
| 2025-06-30 | Reported | -$13.68M* | -$13.72M | $38.00K* | (m) | (m) | (m) | -$10.10M* | (m) | $9.39M | (m) | -$21.00K |
|---|
| 2025-03-31 | Reported | -$11.43M | (m) | (m) | (m) | (m) | (m) | -$13.48M | (m) | $7.81M | (m) | -$11.00K |
|---|
| 2024-12-31 | Reported | -$12.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$14.05M* | -$14.09M | $36.00K* | (m) | (m) | $0.00* | -$9.56M* | (m) | $11.22M | (m) | -$31.00K |
|---|
| 2024-06-30 | Reported | -$13.25M* | -$13.29M | $38.00K* | (m) | (m) | (m) | -$8.68M* | (m) | $10.02M | (m) | -$8.00K |
|---|
| 2024-03-31 | Reported | -$11.87M | (m) | (m) | (m) | (m) | (m) | -$10.47M | (m) | $8.80M | (m) | -$8.00K |
|---|
| 2023-12-31 | Reported | -$8.9M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$9.01M* | -$9.04M | $35.00K* | (m) | (m) | $18.00K* | -$7.28M* | (m) | $6.32M | (m) | -$13.00K |
|---|
| 2023-06-30 | Reported | -$8.35M* | -$8.38M | $34.00K* | (m) | (m) | $40.00K* | -$9.88M* | (m) | $5.84M | (m) | -$30.00K |
|---|
| 2023-03-31 | Reported | -$7.54M | (m) | (m) | (m) | (m) | $57.00K | -$8.20M | (m) | $5.00M | (m) | -$7.00K |
|---|
| 2022-12-31 | Reported | -$6.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$8.40M* | -$8.40M | $9.00K* | (m) | (m) | (m) | -$8.58M* | (m) | $5.77M | (m) | -$7.00K |
|---|
| 2022-06-30 | Reported | -$7.81M* | -$7.82M | $8.00K* | (m) | (m) | (m) | -$6.18M* | (m) | $5.10M | (m) | -$4.00K |
|---|
| 2022-03-31 | Reported | -$7.01M | (m) | (m) | (m) | (m) | (m) | -$7.09M | (m) | $4.64M | (m) | -$5.00K |
|---|
| 2021-09-30 | Reported | (m) | -$6.95M | (m) | (m) | (m) | (m) | -$7.24M* | (m) | $4.72M | (m) | $2.00K |
|---|
| 2021-06-30 | Reported | (m) | -$9.17M | (m) | (m) | (m) | (m) | -$7.90M* | (m) | $6.50M | (m) | -$2.00K |
|---|
| 2021-03-31 | Reported | (m) | -$8.09M | (m) | (m) | (m) | (m) | -$7.58M | (m) | $5.59M | (m) | -$15.00K |
|---|
| 2020-09-30 | Reported | (m) | -$7.24M | (m) | (m) | (m) | $15.00K* | -$6.97M* | (m) | $4.83M | (m) | -$11.00K |
|---|
| 2020-06-30 | Reported | (m) | -$7.41M | (m) | (m) | (m) | (m) | -$8.44M* | (m) | $4.92M | (m) | -$15.00K |
|---|
| 2020-03-31 | Reported | (m) | -$8.64M | (m) | (m) | (m) | (m) | -$4.67M | (m) | $6.02M | (m) | -$9.00K |
|---|
| 2019-09-30 | Reported | (m) | -$7.65M | (m) | (m) | (m) | $0.00* | -$7.73M* | (m) | $5.65M | (m) | -$5.00K |
|---|
| 2019-06-30 | Reported | (m) | -$7.42M | (m) | (m) | (m) | $0.00* | -$5.06M* | (m) | $5.53M | (m) | -$5.00K |
|---|
| 2019-03-31 | Reported | (m) | -$4.81M | (m) | (m) | (m) | $9.00K | -$4.10M | (m) | $3.34M | (m) | -$4.00K |
|---|
| 2018-09-30 | Reported | (m) | -$4.96M | (m) | (m) | (m) | -$1.00K* | -$3.99M* | (m) | $3.75M | (m) | -$25.00K |
|---|
| 2018-06-30 | Reported | (m) | -$4.38M | (m) | (m) | (m) | $10.00K* | -$5.61M* | (m) | $3.44M | (m) | -$25.00K |
|---|
| 2018-03-31 | Reported | (m) | -$3.14M | (m) | (m) | (m) | $57.00K | -$3.95M | (m) | $2.36M | (m) | -$25.00K |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$49.18M | (m) | (m) | (m) | (m) | $12.00K | -$42.09M | (m) | $33.48M | (m) | -$64.00K |
|---|
| 2024-12-31 | Reported | -$51.38M | (m) | (m) | (m) | (m) | $35.00K | -$38.26M | (m) | $39.38M | (m) | -$30.00K |
|---|
| 2023-12-31 | Reported | -$33.8M | (m) | (m) | (m) | (m) | $137.00K | -$31.71M | (m) | $23.68M | (m) | -$32.00K |
|---|
| 2022-12-31 | Reported | -$29.86M | (m) | (m) | (m) | (m) | $159.00K | -$28.18M | (m) | $19.83M | (m) | -$36.00K |
|---|
| 2021-12-31 | Reported | (m) | -$32.48M | (m) | (m) | (m) | (m) | -$28.95M | (m) | $22.98M | (m) | -$21.00K |
|---|
| 2020-12-31 | Reported | (m) | -$32.49M | (m) | (m) | (m) | $32.00K | -$29.00M | (m) | $22.33M | (m) | -$18.00K |
|---|
| 2019-12-31 | Reported | (m) | -$26.64M | (m) | (m) | (m) | $9.00K | -$23.09M | (m) | $19.34M | (m) | -$18.00K |
|---|
| 2018-12-31 | Reported | (m) | -$18.41M | (m) | (m) | (m) | $158.00K | -$18.29M | (m) | $14.07M | (m) | -$124.00K |
|---|